JPH01124749A - Method for measuring multi-sample easily, speedily and high sensitively - Google Patents
Method for measuring multi-sample easily, speedily and high sensitivelyInfo
- Publication number
- JPH01124749A JPH01124749A JP28259187A JP28259187A JPH01124749A JP H01124749 A JPH01124749 A JP H01124749A JP 28259187 A JP28259187 A JP 28259187A JP 28259187 A JP28259187 A JP 28259187A JP H01124749 A JPH01124749 A JP H01124749A
- Authority
- JP
- Japan
- Prior art keywords
- microplate
- sample
- rapid
- sensitivity
- hemoglobin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title abstract description 30
- 239000008280 blood Substances 0.000 claims abstract description 28
- 210000004369 blood Anatomy 0.000 claims abstract description 28
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 18
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 18
- 238000005259 measurement Methods 0.000 claims description 28
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
- 238000000691 measurement method Methods 0.000 claims description 8
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 claims description 6
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 claims description 6
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 claims description 6
- 235000012000 cholesterol Nutrition 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Substances OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- -1 rhodamine isocyanate Chemical class 0.000 claims description 4
- MNIQECRMTVGZBM-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine;7h-purin-6-amine Chemical compound NC1=NC=NC2=C1NC=N2.CN1CCCC1C1=CC=CN=C1 MNIQECRMTVGZBM-UHFFFAOYSA-N 0.000 claims description 2
- SGAOZXGJGQEBHA-UHFFFAOYSA-N 82344-98-7 Chemical compound C1CCN2CCCC(C=C3C4(OC(C5=CC(=CC=C54)N=C=S)=O)C4=C5)=C2C1=C3OC4=C1CCCN2CCCC5=C12 SGAOZXGJGQEBHA-UHFFFAOYSA-N 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 claims description 2
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 claims 2
- 239000012948 isocyanate Substances 0.000 claims 2
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 claims 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 claims 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical group O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims 1
- 229920006130 high-performance polyamide Polymers 0.000 claims 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 23
- 238000012360 testing method Methods 0.000 abstract description 16
- 238000004925 denaturation Methods 0.000 abstract description 7
- 230000036425 denaturation Effects 0.000 abstract description 7
- 239000003960 organic solvent Substances 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 abstract 1
- 239000011358 absorbing material Substances 0.000 abstract 1
- 238000004040 coloring Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 14
- 238000012216 screening Methods 0.000 description 12
- 230000035945 sensitivity Effects 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000011088 calibration curve Methods 0.000 description 8
- HXXFSFRBOHSIMQ-FPRJBGLDSA-N alpha-D-galactose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@H]1O HXXFSFRBOHSIMQ-FPRJBGLDSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229950006238 nadide Drugs 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000048120 Galactokinases Human genes 0.000 description 5
- 108700023157 Galactokinases Proteins 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 5
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 4
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000000834 fixative Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229960003104 ornithine Drugs 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- 208000027472 Galactosemias Diseases 0.000 description 2
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 108010014369 galactose dehydrogenase Proteins 0.000 description 2
- 102000018146 globin Human genes 0.000 description 2
- 108060003196 globin Proteins 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 230000002989 hypothyroidism Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000004143 urea cycle Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NXOIMAMHRHDCFR-UHFFFAOYSA-N 2,3-dihydro-1h-pyrrole-2-carboxylic acid Chemical compound OC(=O)C1CC=CN1 NXOIMAMHRHDCFR-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- 208000019932 Aciduria Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000034318 Argininemia Diseases 0.000 description 1
- 102000004641 Fetal Proteins Human genes 0.000 description 1
- 108010003471 Fetal Proteins Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108010075202 UDP-glucose 4-epimerase Proteins 0.000 description 1
- 108010082433 UDP-glucose-hexose-1-phosphate uridylyltransferase Proteins 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 201000007412 galactokinase deficiency Diseases 0.000 description 1
- 239000007986 glycine-NaOH buffer Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 201000011286 hyperargininemia Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
Abstract
Description
【発明の詳細な説明】
〔利用分野]
本発明は臨床検査における対象試料の少量化、微量化と
多試料の同時処理化と簡便化と迅速化及び省力化を目的
に従来の試験管による反応法を改め、マイクロプレート
容器内における反応法を行い、測定機器としてマイクロ
プレート式蛍光光度計又は吸光光度計にて測定すること
により、種々の蛍光物質と吸収物質例えば還元型ニコチ
ンアデニンジヌクレオチド又還元型ニコチンアミドアデ
ニンジヌクレオチド燐酸(以下これらをNAD (P)
IIという)、p−二トロフェノール、ウンベリフェ
ロン、HPPA−H20□縮合物、チラミン−H,0,
縮合物、F ITCSDTAF、XRITC。[Detailed Description of the Invention] [Field of Application] The present invention aims to reduce the amount of target samples in clinical tests, to minimize the amount, to simultaneously process multiple samples, to simplify, speed up, and save labor. By changing the method and performing the reaction method in a microplate container, and measuring with a microplate fluorometer or spectrophotometer as a measuring device, various fluorescent substances and absorbing substances such as reduced nicotine adenine dinucleotide and reduced type nicotinamide adenine dinucleotide phosphate (hereinafter referred to as NAD (P)
II), p-nitrophenol, umbelliferone, HPPA-H20□ condensate, tyramine-H,0,
Condensate, FITCSDTAF, XRITC.
TRITC,S ITC,コバースフィアーズ(青。TRITC, S ITC, Cover Spheres (Blue.
赤、緑)等蛍光色素の微量定量法の確立により、これら
を反応系にもつ種々の物質例えば酵素活性や基質の測定
が可能となった。又、血液ろ紙デイスクを用いて、血色
素度性固定処理を導入することにより血液試料も容易に
使用できる。しかも微量の資料でよ(、希釈されず多試
料を短時間に処理することが可能になり、最近広く世界
的に実施されている新生児や成人病のマス・スクリーニ
ング検査や癌の集団検査に最適である。The establishment of a microquantitative method for fluorescent dyes (red, green) has made it possible to measure various substances that have these in reaction systems, such as enzyme activities and substrates. In addition, blood samples can be easily used by using a blood filter paper disk and introducing a hemochromatic fixation process. Furthermore, it is now possible to process large numbers of samples in a short time without diluting them with only a small amount of material, making it ideal for mass screening tests for neonatal and adult diseases, as well as mass tests for cancer, which have recently been widely implemented around the world. It is.
従来の測定法は試験管内での反応操作やキュベツトセル
やフローセルや試験管キュベツト内での測定であり、液
量も多く、試料や試薬が希釈により多量必要となり、高
感度の蛍光光度計で測定しても、微量濃度の試薬や試料
測定には適さなかった。又、除蛋白操作など酸、アルカ
リ、塩、重金属、有機溶媒の多量添加と遠心分離操作な
ど煩雑であり、多試料を処理しなければならないマス・
スクリーニングには操作時間、測定時間ともに長時間を
要し、大変な労力を要している。Conventional measurement methods involve reaction operations in test tubes, cuvette cells, flow cells, and test tube cuvettes, which require a large volume of liquid and require large amounts of samples and reagents due to dilution, and require measurements using a highly sensitive fluorometer. However, it was not suitable for measuring trace concentrations of reagents or samples. In addition, protein removal operations are complicated, such as addition of large amounts of acids, alkalis, salts, heavy metals, and organic solvents, and centrifugation operations, and mass processing that requires processing a large number of samples.
Screening requires a long time for both operation and measurement, and requires a lot of effort.
従来の試験管法の欠点である反応液と測定液量の多量性
及び除蛋白や遠心分離操作の煩雑さと測定操作自身も時
間と労力がかかることなど検査試料と溶液量の少量化と
微量化と高感度化、それに迅速性、簡便性、省力化を必
要とするこれからの検査、特に新生児マス・スクリーニ
ング、成人病、癌検査などには解決するためにはいくつ
かの工夫が必要となる。The disadvantages of the conventional test tube method are the large volumes of reaction and measurement solutions, the complexity of protein removal and centrifugation operations, and the time and labor required for the measurement operations themselves. Future tests that require high sensitivity, speed, simplicity, and labor saving, especially newborn mass screening, adult disease, and cancer tests, will require some ingenuity.
〔問題点を解決する手段及びその作用〕貴重な試料の節
約のため、またコストの低下と微量測定のためには反応
系と測定系の液量の少量化が必要である。又、多試料を
同時に一度に短時間に処理(前処理、反応操作、洗浄操
作、測定操作)するためにも、又簡便かつ迅速にしかも
省力化するためにもマイクロプレート容器は大変に有利
である。発明者はこれらの目的に適するように反応系を
工夫改良し、特に微量化に成功した。また血液試料を使
用する場合の除蛋白操作(酸、アルカリ、塩、重金属や
有機溶媒の多量添加)と遠心分離操作の煩わしさ、とり
わけマス・スクリーニングなど多試料検査の場合には長
時間と分力がかかるためさらに新しい工夫が必要となる
。つまり血゛色素は蛍光測定を妨害するため新生児マス
・スクリーニングで実施されているような血液ろ紙とし
て特殊なろ紙に吸着させて、風乾後、打抜き器で適当な
大きさのディスクに打抜き、試験管又はマイクロプレー
ト容器に入れてまず血色素度性固定を行う、これにはい
くつかの方法がある。例えば蟻酸蒸気法や水蒸気変性固
定法や数種類の有機溶媒の特殊な組合わせの系による変
性固定法はたくさんの試料検体を同時に短時間に処理出
来、従来法の様な除蛋白操作や遠心分離操作などで従来
の多大の労力と煩雑さをいつきに解決するものである。[Means for solving the problems and their effects] In order to save valuable samples, reduce costs, and measure trace amounts, it is necessary to reduce the amount of liquid in the reaction system and measurement system. In addition, microplate containers are very advantageous for processing multiple samples at the same time in a short time (pretreatment, reaction operation, washing operation, measurement operation), as well as for being simple, quick, and labor-saving. be. The inventors devised and improved the reaction system to suit these purposes, and were particularly successful in reducing the amount. In addition, when using blood samples, protein removal operations (addition of large amounts of acids, alkalis, salts, heavy metals, and organic solvents) and centrifugation operations are cumbersome and time-consuming, especially in the case of multi-sample tests such as mass screening. Since it takes a lot of force, new innovations are required. In other words, blood pigments are adsorbed onto a special filter paper, such as blood filter paper used in neonatal mass screening, in order to interfere with fluorescence measurements. Or place it in a microplate container and perform hemochromatic fixation first. There are several methods for this. For example, the formic acid vapor method, the steam denaturation fixation method, and the denaturation fixation method using a special combination of several types of organic solvents can process many samples at the same time in a short time, and they do not require protein removal or centrifugation like conventional methods. This will instantly solve the huge amount of effort and complexity that was involved in the past.
a)蟻酸蒸気法
密閉容器中に蟻酸98%を入れたビーカーを入れ、試料
を入れたマイクロプレートを入れ密閉し、蟻酸の飽和蒸
気で室温、1時間放置し、血色素の変性固定する。とり
出したマイクロプレートに付着した酸を除去するために
コック付のデシケータ−に入れて水流ポンプで吸引し、
コックを止めて37°Cの恒温器に数時間入れておくか
ドライヤーで飛ばす。a) Formic acid vapor method A beaker containing 98% formic acid is placed in a sealed container, a microplate containing a sample is placed in the container, the container is sealed, and the container is left in saturated vapor of formic acid at room temperature for 1 hour to denature and fix hemoglobin. In order to remove the acid attached to the removed microplate, it was placed in a desiccator with a stopcock and suctioned with a water pump.
Turn off the cook and put it in a 37°C thermostat for several hours, or blow it away with a hair dryer.
b)水蒸気変性固定法
水蒸気の温度80〜85℃に保ち、10分間蒸気に試料
をさらすと血色素が変性固定する。湿った血液ろ紙は3
7℃の恒温器中で乾燥させるかドライヤーで乾燥する。b) Steam denaturation fixation method The hemoglobin is denatured and fixed by keeping the steam temperature at 80-85°C and exposing the sample to the steam for 10 minutes. The moist blood filter paper is 3
Dry in a constant temperature oven at 7°C or dry with a hair dryer.
C)有機溶媒による変性固定法
水:アセトン:メタノール(20:20:60%)の混
合糸とエーテル又はメチレンクロライドの比を1:3〜
5にした通常の溶媒液を10〜20μ2血液ろ紙デイス
クに加える。通常のマイクロプレートは溶媒に弱いので
塩化ビニール製のプレートを使う。37°C130分間
放置する。C) Modification fixation method using organic solvent The ratio of water: acetone: methanol (20:20:60%) mixed thread and ether or methylene chloride is 1:3 to 1:3.
Add 10-20μ2 of normal solvent solution at 5 to 2 blood filter paper disks. Ordinary microplates are sensitive to solvents, so plates made of vinyl chloride are used. Leave at 37°C for 130 minutes.
さらに本発明の利点は試料が希釈されないため測定感度
を著しく高め、微量化が可能となったことである。又、
アイソトープなどを使用することなく生体中特に血液中
の酵素活性を多試料同時に処理測定出来るように血色素
蛋白のみをろ紙に固定するが、酵素蛋白は容易に抽出で
きる血色素置定法を開発した(実施例6)。Furthermore, the advantage of the present invention is that since the sample is not diluted, the measurement sensitivity is significantly increased and it is possible to reduce the amount of the sample. or,
We have developed a hemoglobin fixation method that fixes only the hemoglobin protein on filter paper so that enzyme activity in living organisms, especially blood, can be processed and measured simultaneously in multiple samples without using isotopes, etc., but the enzyme protein can be easily extracted (Example 6).
マイクロプレートの使用はこれまでにもESISA法が
工夫されてきているが現在使用されているのは吸光度計
による方式であるため限界があり、特に高感度の蛍光測
定がひつような生体内の微量物質、例えば微量ホルモン
や血液代謝産物等の多試料迅速測定にはマイクロプレー
ト方式の高感度蛍光光度針が必要となる。The ESISA method has been devised to date for the use of microplates, but the method currently used is based on an absorbance meter, which has its limitations, especially when measuring trace amounts in vivo, where highly sensitive fluorescence measurements are required. Rapid multi-sample measurement of substances such as trace hormones and blood metabolites requires a microplate-based highly sensitive fluorescence needle.
血中の物質濃度の多くは10−6〜10−1°Mあたり
である。通常の測定器の検出限界は例えばコロナ電気製
MTP22Fやタイターチック社製フルオロスキャンは
10−h〜10−” Mが限界であったが最近開発さ
れたコロナ電気製MTP32Fや100Fを使用すれば
10−6〜10−” Mの測定が可能となり、高感度の
測定が期待出来ることから測定物質の利用分野と対象が
広がった。このような微量に対する感度が向上した測定
器を使用すれば本発明のような前処理、反応操作、洗浄
操作、測定操作など一度に多試料同時に短時間に終了さ
せることが出来るマイクロプレート方式はマス・スクリ
ーニングの検査には最適となる。Most of the substance concentrations in blood are around 10-6 to 10-1 °M. The detection limit of conventional measuring instruments, for example Corona Electric's MTP22F and Titertic's Fluoroscan, is 10-h to 10-''M, but the recently developed Corona Electric's MTP32F and 100F can be used to reach 10 Since it has become possible to measure -6 to 10-''M, and highly sensitive measurements can be expected, the fields and objects of use of the substance to be measured have expanded. If a measuring instrument with improved sensitivity to such small amounts is used, the microplate method of the present invention, which can complete pretreatment, reaction operations, washing operations, and measurement operations for many samples at once in a short time, will become a mass market.・Ideal for screening tests.
本発明の応用対象としては例えば新生児マス・スクリー
ニング検査法として、ガラクトース血症発見のため血中
ガラクトースとガラクトース−1−Pの定量、ガラクト
キナーゼ、ウリジンニ燐酸−ガラクトース−4−エピメ
ラーゼやウリジルトランスフエレース活性や甲状腺機能
低下症(フレチン症)のTSHやT4の測定、副腎皮質
過形成の17α−ハイドロオキシプロジェストロン(1
7α−0HP)の測定、尿素サイクル代謝異常症のオル
ニチン血症、アルギニン血症、アルギノコハク酸尿症等
の検査法、NAD(P)Hを補酵素とする代謝産物の臨
床検査、インシュリンや胎児性、フェトプロティンの測
定及び新生児、成人血色素とコレステロールの測定など
枚挙すれば限りがない。The present invention can be applied, for example, as a newborn mass screening test, for the determination of galactose and galactose-1-P in the blood to detect galactosemia, galactokinase, uridine diphosphate-galactose-4-epimerase, and uridyltransferase. Measurement of TSH and T4 for hypothyroidism and hypothyroidism (fretinism), 17α-hydroxyprogesterone (17α-hydroxyprogesterone) for adrenal cortical hyperplasia
7α-0HP), testing methods for urea cycle metabolic disorders such as ornithineemia, argininemia, and arginosuccinic aciduria, clinical tests for metabolites with NAD(P)H as a coenzyme, insulin and fetal , Fetoprotein measurement, newborn and adult hemoglobin and cholesterol measurements, the list is endless.
次に実施例をあげて説明するが本発明はこれにより制限
されるものでない。Next, the present invention will be described with reference to examples, but the present invention is not limited thereto.
実施例1.ウンベリフェロンの迅速定量ウンベリフェロ
ンの迅速定量はコロナ電気製MTP32F又は22F型
のマイクロプレート方式蛍光光度計のホトマルチプライ
ヤにかけた電圧を変えることにより高濃度から低濃度ま
で目的に合った濃度を測定することが出来る。図−1は
各光度計による測定範囲を示している。図中の数字はウ
ンベリフェロンの各濃度100μrと負荷電圧を示す。Example 1. Rapid quantification of umbelliferone Rapid quantification of umbelliferone is achieved by changing the voltage applied to the photomultiplier of a Corona Electric MTP32F or 22F microplate type fluorometer to adjust the concentration from high to low. It can be measured. Figure 1 shows the measurement range of each photometer. The numbers in the figure indicate each concentration of umbelliferone, 100 μr, and the load voltage.
コロナ電気製MTP22F型、タイターチックのフルオ
ロスキャンは10−6〜10−7〜(10−1l)M、
コロナ電気製MTP32Fは10−h〜10−9〜(1
0−”)M、コロナ電気製試験管挿入型FPMIIは1
0−6〜10− ’ ”〜(10−” ) Mの測定に
適している。Corona Electric's MTP22F type, Titertic's Fluoroscan is 10-6 ~ 10-7 ~ (10-1 l) M,
Corona Electric MTP32F is 10-h~10-9~(1
0-”)M, Corona Electric test tube insertion type FPMII is 1
Suitable for measurement of 0-6 to 10-''' to (10-'')M.
高電圧にすると蛍光強度は高まる。When the voltage is increased, the fluorescence intensity increases.
実施例2.TSHの高感度迅速測定によるマス・スクリ
ーニング法
抗TSH・IgG固相プレートの各ウェルに標準血液ろ
紙又は一般検体血液ディスク4IIII+1個(血液4
〜6μl)、β−ガラクトース脱水素酵素標識抗ヒトT
SHウサギIgG血清100μlを混和し、シールをプ
レートにはり、37°Cにて一夜反応させ、内容物を除
去し、0.01Mリン酸緩衝液(pH7,4)−0,I
M NaC1−1mM MgC1z (Tween 2
0を含む)300μlで3回洗浄する。この間にろ紙デ
イスクを除去する。4−メチルウンベリフェリル−β−
D−ガラクトシド100μiを加えて、37°c11時
間反応後、反応停止液0.1Mグリシン−NaOH緩衝
液(pH10,3)を200ul加えて混和し、コロナ
電気製MTP32Fでホトマル250〜300■でE
X365nn+ Ets 450ntaで測定する。図
−2はTSHの検量線である。Example 2. Mass screening method using highly sensitive and rapid measurement of TSH Standard blood filter paper or general sample blood disk 4III + 1 (blood 4
~6 μl), β-galactose dehydrogenase labeled anti-human T
Mix 100 μl of SH rabbit IgG serum, put a seal on the plate, react overnight at 37°C, remove the contents, and add 0.01M phosphate buffer (pH 7.4)-0.I.
M NaC1-1mM MgC1z (Tween 2
Wash 3 times with 300 μl (containing 0). During this time, remove the filter paper disc. 4-Methylumbelliferyl-β-
After adding 100 μi of D-galactoside and reacting at 37°C for 11 hours, add 200 μl of 0.1 M glycine-NaOH buffer (pH 10,3) as a reaction stop solution and mix.
Measured with X365nn+ Ets 450nta. Figure 2 shows the TSH calibration curve.
実施例3.NAD(P)Hの迅速定量
NAD (P) Hの迅速定量はマイクロプレートの各
セルにNADH溶液100μ2を入れてコロナ電気製M
TP32Fでホトマルの負荷電圧を変えることにより、
低濃度から高濃度までの目的に合った濃度を測定出来る
。図−3はホトマルチプライヤの電圧が300vのとき
NADHの測定範囲として感度1ではN A D HO
〜40nmol / 100 u lを、感度2ではO
〜2nmol/100μiと高感度測定が出来る。Example 3. Rapid quantification of NAD(P)H For rapid quantification of NAD(P)H, place 100μ2 of NADH solution in each cell of a microplate and use Corona Electric's M
By changing the photomal load voltage with TP32F,
Concentrations suitable for purposes can be measured from low to high concentrations. Figure 3 shows the NADH measurement range when the photomultiplier voltage is 300V.At sensitivity 1, NADH
~40 nmol/100 ul in O at sensitivity 2
High sensitivity measurement of ~2nmol/100μi is possible.
実施例4.血中ガラクトース(Gal)及びガラクトー
ス−1−P (Gal−1−P)の定量反応系1 :
(Gal+Gal−1−P)は13mM NAD 10
u l 。Example 4. Blood galactose (Gal) and galactose-1-P (Gal-1-P) quantitative reaction system 1:
(Gal+Gal-1-P) is 13mM NAD 10
ul.
1Mトリス塩酸(pH8,0) 10μl、アルカリホ
スファターゼ(AP、ベーリンガー) 10,0OOU
/d1μ!、β−ガラクトース脱水素酵素(β−Gal
−DH)9μ2と血液試料か標準ガラクトース含有血液
ろ紙(0〜3mM) (血色素度性固定処理のろ紙デ
ィスク3+@+m径1個)又はGal水溶液0〜4 r
tmol 。1M Tris-HCl (pH 8.0) 10 μl, alkaline phosphatase (AP, Boehringer) 10.0 OOU
/d1μ! , β-galactose dehydrogenase (β-Gal
-DH) 9μ2 and blood sample or standard galactose-containing blood filter paper (0-3mM) (1 piece of filter paper disk 3+@+m diameter with hemoglobin fixation treatment) or Gal aqueous solution 0-4 r
tmol.
計30μ!
反応系2 : (Gal)は反応系1よりAPを除き蒸
留水を入れる。Total 30μ! Reaction system 2: For (Gal), remove AP from reaction system 1 and add distilled water.
反応系3 : (Blank)は反応lよりβ−Gal
−DHのみ除き蒸留水を入れる。Reaction system 3: (Blank) is β-Gal from reaction 1
- Remove only DH and add distilled water.
各反応系をマイクロプレート中で37°C,1時間行い
、蒸留水か緩衝液100μlを加えてよく混和し、その
100μ尼を別のマイクロプレートに移す。Perform each reaction system in a microplate at 37°C for 1 hour, add 100 μl of distilled water or buffer, mix well, and transfer the 100 μl to another microplate.
図−4はGal とGal−1−Pとの検量線を示す。Figure 4 shows the calibration curve of Gal and Gal-1-P.
Gal−1−P量は反応系1−2より、Gal量は反応
系2−3より計算し検量線から求める。又、蛍光強度は
マイクロプレートの製品によって大きな差があり、各ウ
ェルのばらつきの少ないプレートを選ぶべきである。図
−5は末法と従来法との相関を示し、r 〜0.959
と良く相関することを示している。The amount of Gal-1-P is calculated from reaction system 1-2, and the amount of Gal is calculated from reaction system 2-3, and determined from the calibration curve. Furthermore, the fluorescence intensity varies greatly depending on the type of microplate, so a plate with little variation among wells should be selected. Figure 5 shows the correlation between the final method and the conventional method, r ~ 0.959
It shows that there is a good correlation with
実施例5.尿素サイクル代謝異常症のマス・スクリーニ
ング法、血中オルニチンの微量
定量
マイクロプレートの各ウェルに反応系として、トリス塩
酸(pH8,0) 5 μmol 、α−ケトグルタル
酸0.25 μmol 、ジチオスライトール0.5n
mol、ピロリン−5−カルボン酸還元酵素(天野製薬
製)3.7ml+ 、オルニチン転移酵素(天野製薬製
)3.7m1l 、 NADH3〜5nmol、オルニ
チン O〜2nmol又は0〜2mMの血液ろ紙デイス
クか検査血液ろ紙デイスク(血色素度性固定処理後の3
mm径1個)、計50μ!、対照としては試料を入れな
い反応系である。反応は37°C11時間後蒸留水80
μ2を加えて混和し、その100μlを別のマイクロプ
レートに移し測定する。図−6は検量線を示し、CV
3.1〜6.0%、オルニチ71mM(7)血液ディス
ク3mm1個が2.1nmolに相当する。Example 5. Mass screening method for urea cycle metabolic disorder, trace amount determination of blood ornithine In each well of a microplate, 5 μmol of Tris-HCl (pH 8,0), 0.25 μmol of α-ketoglutaric acid, 0 dithiothreitol was added as a reaction system. .5n
mol, pyrroline-5-carboxylic acid reductase (manufactured by Amano Pharmaceutical) 3.7ml+, ornithine transferase (manufactured by Amano Pharmaceutical) 3.7ml, NADH 3-5nmol, ornithine O-2nmol or 0-2mM blood filter paper disk or test blood Filter paper disk (3 after hemochromatic fixation treatment)
1 mm diameter), total 50μ! The control is a reaction system in which no sample is added. The reaction was carried out at 37°C for 11 hours, then with distilled water at 80°C.
Add μ2, mix, and transfer 100 μl to another microplate for measurement. Figure-6 shows the calibration curve, and CV
3.1 to 6.0%, 71 mM (7) One 3 mm blood disc corresponds to 2.1 nmol.
実施例6.酵素活性を失活させない新しい血色素置定法
用いる血色素固定液はまず最初にA液〔水:アセトン:
メタノール(30:35:35%)〕10μlを各試料
に加えて37℃、30分間乾燥固定させ、次いでB液〔
水:アセトン:メタノール(20:20:60%)〕と
エーテル又は塩化メチレンの3〜5:1の混合系10〜
20μlを加えて37℃、30分間放置すればほぼ血色
素は固定されるが酵素蛋白は失活せず抽出出来る。Example 6. The hemoglobin fixative used in the new hemoglobin fixation method that does not deactivate enzyme activity is first of all solution A [water: acetone:
Add 10 μl of methanol (30:35:35%) to each sample, dry and fix at 37°C for 30 minutes, and then add solution B [
Mixture system of water:acetone:methanol (20:20:60%) and ether or methylene chloride in a ratio of 3 to 5:110 to
If 20 μl is added and left at 37°C for 30 minutes, most of the hemoglobin will be fixed, but the enzyme protein will not be deactivated and can be extracted.
B液として使用できるのは以下のいくつかの系である。The following systems can be used as liquid B.
例えば
(10:10:80) 115(20:1
0ニア0) 115〜1/1(20: 6
0 : 20) 3 / 1〜1/1(2
0:10ニア0) l10(10:80:
10) 1./1〜1/4(30:10:
60) 1/4(30: 35 : 35
) 1 / 1〜1/4実施例7.微量血
色素の筒便迅速測定法マイクロプレートに血液ディスク
3fflIIIφ1個(2,5μりを入れ、ヘモグロビ
ン測定液200μ2を加える。標準液としてアキュート
グロビンの原液と1/2希釈液200μ2を使用して、
37°C130分間反応後、別の測定用プレートにその
100μ2を分注してコロナ電気製マイクロプレート吸
光光度計MTP32を用いて、A 55゜の吸収を測定
する。図−7は検量線を示し、図−8は乾燥血液ろ紙デ
イスクとヘモグロビン量の定量性を示す。For example (10:10:80) 115 (20:1
0 near 0) 115~1/1 (20: 6
0:20) 3/1~1/1(2
0:10 near 0) l10 (10:80:
10) 1. /1~1/4 (30:10:
60) 1/4 (30: 35: 35
) 1/1 to 1/4 Example 7. Rapid fecal measurement method for trace hemoglobin Place one 3fflIIIφ blood disk (2.5μ) into a microplate and add 200μ2 of hemoglobin measurement solution.Use 200μ2 of the stock solution and 1/2 diluted solution of acute globin as the standard solution.
After reacting at 37°C for 130 minutes, 100μ2 of the solution was dispensed into another measurement plate, and the A 55° absorption was measured using Corona Electric Microplate Absorption Photometer MTP32. Figure 7 shows a calibration curve, and Figure 8 shows dried blood filter paper disks and quantitative properties of hemoglobin amount.
実施例8.ガラクトカイネース欠損症の新しいマス・ス
クリーニング法(ガラクトキナ
ーゼの簡便迅速測定法)
Gal 1mM、 NaF 1mM、 MgC
Iz 8mM++ DTT 10℃飢 八TP
60〜120mM、サポニン0.01%、過酸化水素0
.01%、 Tris−HCI(pH7,4) 200
mM、ディスク1個で反応液100μ2を37°C16
0分間〜90分間反応させ、NAD IOIIIM 1
0,1/ L β−Gal−DH原液25U/mj!
X1150〜1 /200希釈液10μ2を加えて反応
させ(37°C11時間)、その60μ2をグイナテッ
ク製の測定用白色プレートに分注して、コロナ電気製マ
イクロプレート用蛍光光度計MTP32FでEx365
nm、 Em 450nmでPM 250V、感度1で
測定する。Example 8. New mass screening method for galactokinase deficiency (simple and rapid measurement method for galactokinase) Gal 1mM, NaF 1mM, MgC
Iz 8mM++ DTT 10℃ starvation 8TP
60-120mM, saponin 0.01%, hydrogen peroxide 0
.. 01%, Tris-HCI (pH 7,4) 200
mM, 100μ2 of reaction solution per disk at 37°C16
0 minutes to 90 minutes, NAD IOIIIM 1
0,1/L β-Gal-DH stock solution 25U/mj!
Add 10 μ2 of a diluted solution of
Measured at PM 250V, sensitivity 1 at Em 450nm.
この場合前処理として血液ディスクの血色素炭性固定を
行う。このときガラクトキナーゼ活性は失活しないで抽
出出来る固定液を使用する。まずFalconの薄いデ
ィスポーサブルプレートに血液検体ディスク3mm−1
個を入れ、有機溶媒混合固定液A液10alずつ入れ、
37℃、15〜30分間放−置、さ装に同固定液Bとエ
ーテル比3/1の溶剤10μ!を加えて、37°C13
0分間処理してから反応液を入れる。又、ブランクのデ
ィスクは蟻酸蒸気固定か水蒸気固定(120’C11o
分)を行う。In this case, as a pretreatment, hemoglobin charcoal fixation of the blood disk is performed. At this time, a fixative solution is used that can extract galactokinase activity without inactivating it. First, place a 3mm-1 blood sample disk on a Falcon thin disposable plate.
and 10 al of organic solvent mixed fixative solution A solution each.
Leave it at 37°C for 15-30 minutes, and add 10μ of the same fixative B and a solvent with an ether ratio of 3/1! Add and heat to 37°C13
After processing for 0 minutes, add the reaction solution. In addition, blank discs are fixed with formic acid vapor or water vapor (120'C11o).
minutes).
・結果
図−9に示すように、蛍光強度が0〜200の範囲でガ
ラクトキナーゼ量と蛍光強度の間に直線関係が成り立ち
、定量できることが確認された。-Results As shown in Figure 9, it was confirmed that a linear relationship was established between the amount of galactokinase and the fluorescence intensity in the fluorescence intensity range of 0 to 200, and that quantification was possible.
実施例9.高コレステロール血症のマス・スクリーニン
グ
実施例5の方法に準じて血色素の変性固定処理後、抽出
操作を行い、コレステロール測定用キット(ステロザイ
ム545、富士レビオ社製)を用いて測定した。その結
果、コレステロール濃度がO〜800■/d1の範囲に
おいて良好な直線性が得られ、添加回収率も95〜10
5%と良好であった。Example 9. Mass screening for hypercholesterolemia Following the denaturation and fixation treatment of hemoglobin according to the method of Example 5, extraction was performed and the cholesterol measurement was performed using a cholesterol measurement kit (Sterozyme 545, manufactured by Fujirebio). As a result, good linearity was obtained in the cholesterol concentration range of 0 to 800 μ/d1, and the addition recovery rate was 95 to 10.
It was a good 5%.
本発明により、従来より簡便で且つ迅速に多くの試料を
検査することができ、マス・スクリーニング等が高感度
に行えるようになった。According to the present invention, many samples can be tested more easily and quickly than ever before, and mass screening can now be performed with high sensitivity.
図−1はウンベリフェロンの定量結果を示すものであり
、−拳一、−・−1−一・−−は各々コロナFPM11
による負荷電圧750■、550■、440■の結果で
あり、−ム一は各々コロナMTP22Fによる結果であ
り、−0−はコロナMTP32Fによる結果である。図
−2はTSHの検量線を示す。図−3はNADHと蛍光
強度の関係を示すものであり、−・−1−0−は各々感
度1、感度2の結果である。図−4はGal、Gal−
1−Pと蛍光強度の関係を示すものであり、−・−1−
0−は各々感度1、感度2の結果である。図−5は本性
と従来法との相関関係を示す。図−6はオルニチンの検
量線を示す。図−7はアキュートグロビンの検量線を示
す。図−8は血液ディスクの数とヘモグロビン量の関係
を示す。図−9はガラクトキナーゼと蛍光強度の関係を
示す。Figure-1 shows the quantitative results of umbelliferone, and -Kenichi, -1-1, and - respectively indicate Corona FPM11.
These are the results for load voltages of 750■, 550■, and 440■, respectively, -0- is the result for Corona MTP22F, and -0- is the result for Corona MTP32F. Figure 2 shows the TSH calibration curve. Figure 3 shows the relationship between NADH and fluorescence intensity, where -1-0- are the results for sensitivity 1 and sensitivity 2, respectively. Figure-4 is Gal, Gal-
It shows the relationship between 1-P and fluorescence intensity, -・-1-
0- is the result of sensitivity 1 and sensitivity 2, respectively. Figure 5 shows the correlation between the nature and the conventional method. Figure 6 shows the calibration curve for ornithine. Figure 7 shows the calibration curve of acute globin. Figure 8 shows the relationship between the number of blood discs and the amount of hemoglobin. Figure 9 shows the relationship between galactokinase and fluorescence intensity.
Claims (1)
度マイクロプレート用蛍光光度計や吸光光度計を組合わ
せることを特徴とする簡便迅速な多試料高感度測定法。 2)測定試料として乾燥血液ろ紙を用いる特許請求の範
囲第1項記載の簡便迅速な多試料高感度測定法。 3)還元型ニコチンアデニンジヌクレオチド又還元型ニ
コチンアミドアデニンジヌクレオチド燐酸、ウンベリフ
ェロン又は4−メチルウンベリフェロン、3−p−ヒド
ロキシフェニルプロピオン酸(HPPA)−過酸化水素
縮合物及びチラミン−過酸化水素縮合物、ニトロフェノ
ールを含む特許請求の範囲第1項及び第2項記載の簡便
迅速な多試料高感度測定法。 4)蛍光色素がフルオレッセンイソチオシアネート(F
ITC)、デクロロトリアジニルフルオレッセン(DT
AF)、ローダミンイソシアネート(XRITC)、テ
トラメチルローダミンイソシアネート(TRITC)、
4−アセトアミド−4″−イソチオシアノスチベン−2
,2′−デスルホン酸(SITC)、コバスフィアーズ
(青、赤、緑)である特許請求の範囲第1項及び第2項
記載の簡便迅速な多試料高感度測定法。 5)測定対象がヘモグロビンである特許請求の範囲第1
項及び第2項記載の簡便迅速な多試料高感度測定法。 6)測定対象がコレステロールである特許請求の範囲第
1項及び第2項記載の簡便迅速な多試料高感度測定法。[Claims] 1) A simple and rapid multi-sample high-sensitivity measurement method characterized by using a microplate or a strip cell in combination with a high-sensitivity microplate fluorometer or spectrophotometer. 2) A simple, rapid, and highly sensitive multi-sample measurement method according to claim 1, which uses dried blood filter paper as a measurement sample. 3) Reduced nicotine adenine dinucleotide or reduced nicotinamide adenine dinucleotide phosphate, umbelliferone or 4-methylumbelliferone, 3-p-hydroxyphenylpropionic acid (HPPA)-hydrogen peroxide condensate, and tyramine-peroxide condensate. The simple, rapid, multi-sample, high-sensitivity measurement method according to claims 1 and 2, which comprises a hydrogen oxide condensate and nitrophenol. 4) The fluorescent dye is fluorescein isothiocyanate (F
ITC), dechlorotriazinylfluorescein (DT
AF), rhodamine isocyanate (XRITC), tetramethyl rhodamine isocyanate (TRITC),
4-acetamido-4″-isothiocyanostiben-2
, 2'-desulfonic acid (SITC), and Cobaspheres (blue, red, green). 5) Claim 1 in which the measurement target is hemoglobin
The simple, rapid, multi-sample, high-sensitivity measurement method described in Sections 1 and 2. 6) A simple, rapid, multi-sample, high-sensitivity measurement method according to claims 1 and 2, wherein the measurement target is cholesterol.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP28259187A JPH01124749A (en) | 1987-11-09 | 1987-11-09 | Method for measuring multi-sample easily, speedily and high sensitively |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP28259187A JPH01124749A (en) | 1987-11-09 | 1987-11-09 | Method for measuring multi-sample easily, speedily and high sensitively |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH01124749A true JPH01124749A (en) | 1989-05-17 |
Family
ID=17654499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP28259187A Pending JPH01124749A (en) | 1987-11-09 | 1987-11-09 | Method for measuring multi-sample easily, speedily and high sensitively |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH01124749A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010037908A1 (en) * | 2008-10-03 | 2010-04-08 | Wallac Oy | Method and apparatus for detecting elution of samples |
-
1987
- 1987-11-09 JP JP28259187A patent/JPH01124749A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010037908A1 (en) * | 2008-10-03 | 2010-04-08 | Wallac Oy | Method and apparatus for detecting elution of samples |
EP3734253A1 (en) * | 2008-10-03 | 2020-11-04 | Wallac OY | Apparatus for detecting elution of samples |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Thiessen et al. | Conversion of a laboratory-based test for phenylalanine detection to a simple paper-based format and implications for PKU screening in low-resource settings | |
Parween et al. | An affordable, rapid determination of total lipid profile using paper-based microfluidic device | |
US5162202A (en) | Rectal mucus test and kit for detecting cancerous and precancerous conditions | |
CN110596396B (en) | Method for detecting protein, test strip and kit | |
Yamaguchi et al. | Microassay for screening newborns for galactosemia with use of a fluorometric microplate reader. | |
Li et al. | Immobilized enzymatic fluorescence capillary biosensor for determination of sulfated bile acid in urine | |
US3682586A (en) | Process for the determination of creatinine body fluids | |
Annino et al. | Determination of 3-methoxy-4-hydroxymandelic acid (VMA) in urine by thin-layer chromatography | |
CN107860729B (en) | Stable reagent for determining glutamic-oxalacetic transaminase | |
JPH01124749A (en) | Method for measuring multi-sample easily, speedily and high sensitively | |
CN110596378A (en) | Multichannel universal chromatography method for detecting small molecules, test strip and kit | |
EP4085245B1 (en) | Method and device for analysis of liquid samples | |
CN113655227A (en) | Multi-connected detection kit for screening neonatal diseases, and preparation method and use method thereof | |
CN101221129B (en) | Sulfated bile acid enzyme fluorescence capillary analytical method and enzyme fluorescence quantitative reagent kit | |
Getchell et al. | Direct automated determination of glucose by a glucose oxidase-peroxidase system | |
Asp | Improved method for the assay of phenylglycosidase activity with a 4-aminoantipyrine reagent | |
Li et al. | A novel analysis method for lactate dehydrogenase activity in serum samples based on fluorescence capillary analysis | |
JP2005537022A (en) | Homocysteine assay applicable to screening | |
EP3404418A2 (en) | A diagnostic strip for determining the amount of sarcosine, creatinine and hydrogen peroxide in a biological or environmental sample | |
JP2005304483A (en) | Method for measuring alkaline phosphatase | |
US3923459A (en) | Process for the determination of bilirubin in fluids | |
Quraishi et al. | Effect of storage temperature on cholesterol measurement from dried blood | |
JPS5913197B2 (en) | Bile acid measurement method | |
CN111638324B (en) | Coronary heart disease diagnosis biomarker composition and application thereof | |
Fujimura et al. | A new method of blood galactose estimation for mass screening of galactosemia |